Overview

Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy and safety of axatilimab in participants with IPF.
Phase:
Phase 2
Details
Lead Sponsor:
Syndax Pharmaceuticals
Collaborator:
DevPro Biopharma